These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36648742)

  • 41. Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events.
    Zhang Y; Pletcher MJ; Vittinghoff E; Clemons AM; Jacobs DR; Allen NB; Alonso A; Bellows BK; Oelsner EC; Zeki Al Hazzouri A; Kazi DS; de Ferranti SD; Moran AE
    JAMA Cardiol; 2021 Dec; 6(12):1406-1413. PubMed ID: 34550307
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients.
    Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sustained low-density lipoprotein-cholesterol <70 mg/dl is associated with improved cardiovascular outcomes in the clinical setting.
    Sánchez-Bacaicoa C; Galán J; Guijarro C; Rico-Martín S; Monreal M; Calderón-García JF; Aguilar-Cortés E; Sánchez Muñoz-Torrero JF;
    Eur J Clin Invest; 2022 May; 52(5):e13732. PubMed ID: 34908162
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population.
    Séguro F; Bongard V; Bérard E; Taraszkiewicz D; Ruidavets JB; Ferrières J
    Arch Cardiovasc Dis; 2015 Oct; 108(10):511-8. PubMed ID: 26073227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
    Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.
    Giugliano RP; Wiviott SD; Blazing MA; De Ferrari GM; Park JG; Murphy SA; White JA; Tershakovec AM; Cannon CP; Braunwald E
    JAMA Cardiol; 2017 May; 2(5):547-555. PubMed ID: 28291866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study.
    Chang CH; Yeh ST; Ooi SW; Li CY; Chen HF
    PeerJ; 2023; 11():e14609. PubMed ID: 36643628
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atherosclerotic cardiovascular disease risk and small dense low-density lipoprotein cholesterol in men, women, African Americans and non-African Americans: The pooling project.
    Schaefer EJ; Ikezaki H; Diffenderfer MR; Lim E; Liu CT; Hoogeveen RC; Guan W; Tsai MY; Ballantyne CM
    Atherosclerosis; 2023 Feb; 367():15-23. PubMed ID: 36724690
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
    Duell PB; Gidding SS; Andersen RL; Knickelbine T; Anderson L; Gianos E; Shrader P; Kindt I; O'Brien EC; McCann D; Hemphill LC; Ahmed CD; Martin SS; Larry JA; Ahmad ZS; Kullo IJ; Underberg JA; Guyton J; Thompson P; Wilemon K; Roe MT; Rader DJ; Cuchel M; Linton MF; Shapiro MD; Moriarty PM; Knowles JW
    Atherosclerosis; 2019 Oct; 289():85-93. PubMed ID: 31487564
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
    Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of Incident Atherosclerotic Cardiovascular DiseaseEvents by Achieved Atherogenic Lipid Levels Among62,428 Statin-Treated Individuals With Diabetes Mellitus.
    Rana JS; Liu JY; Moffet HH; Boklage SH; Khan I; Karter AJ
    Am J Cardiol; 2018 Sep; 122(5):762-767. PubMed ID: 30057224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification.
    Rana JS; Virani SS; Moffet HH; Liu JY; Coghlan LA; Vasadia J; Ballantyne CM; Karter AJ
    Am J Med; 2022 May; 135(5):603-606. PubMed ID: 34861203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
    Hagström E; Steg PG; Szarek M; Bhatt DL; Bittner VA; Danchin N; Diaz R; Goodman SG; Harrington RA; Jukema JW; Liberopoulos E; Marx N; McGinniss J; Manvelian G; Pordy R; Scemama M; White HD; Zeiher AM; Schwartz GG;
    Circulation; 2022 Aug; 146(9):657-672. PubMed ID: 35770629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
    Lu Y; Zhang H; Lu J; Ding Q; Li X; Wang X; Sun D; Tan L; Mu L; Liu J; Feng F; Yang H; Zhao H; Schulz WL; Krumholz HM; Pan X; Li J;
    JAMA Netw Open; 2021 Sep; 4(9):e2127573. PubMed ID: 34586366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
    Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
    J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Increased lipoprotein(a) in a paediatric patient associated with nephrotic syndrome].
    Menéndez Valladares P; Arrobas Velilla T; Bermúdez de la Vega JA; Romero Pérez MD; Fabiani Romero F; González Rodríguez C
    Clin Investig Arterioscler; 2016; 28(5):227-229. PubMed ID: 27623226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.